Fine tuning of the innate and adaptive immune responses by Interleukin-2

References

• Baek S, Kim Y-M, Kim S-B, Kim C-S, Kwon S-W, Kim Y, Kim H, Lee H. 2015. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: A Phase I/II trial. Cell Mol Immunol. 12(1):87–95. doi: 10.1038/cmi.2014.40.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. 1998. Dendritic cells and the control of immunity. Nature. 392(6673):245–252. doi: 10.1038/32588.
   PubMed Web of Science ®Google Scholar
• Barron L, Dooms H, Hoyer KK, Kuswanto W, Hofmann J, O‘Gorman WE, Abbas AK. 2010. Cutting edge: Mechanisms of IL-2-dependent maintenance of functional regulatory T-cells. J Immunol. 185(11):6426–6430. doi: 10.4049/jimmunol.0903940.
   PubMed Web of Science ®Google Scholar
• Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, et al. 2018. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 24(8):1178–1191. doi: 10.1038/s41591-018-0085-8.
   PubMed Web of Science ®Google Scholar
• Bendickova K, Fric J. 2020. Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy. J Leukoc Biol. 108(1):427–437. doi: 10.1002/JLB.5MIR0420-055R.
   PubMed Web of Science ®Google Scholar
• Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis e Sousa C, et al. 2018. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 172(5):1022–1037 e14. doi: 10.1016/j.cell.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. 2012. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 12(3):180–190. doi: 10.1038/nri3156.
   PubMed Web of Science ®Google Scholar
• Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, et al. 2014. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T-cell immunity. Cancer Cell. 26(6):938. doi: 10.1016/j.ccell.2014.11.010.
   PubMed Web of Science ®Google Scholar
• Chen M, Wang Y-H, Wang Y, Huang L, Sandoval H, Liu Y-J, Wang J. 2006. Dendritic cell apoptosis in the maintenance of immune tolerance. Science. 311(5764):1160–1164. doi: 10.1126/science.1122545.
   PubMed Web of Science ®Google Scholar
• Coombes JL, Siddiqui KRR, Arancibia-Cárcamo CV, Hall J, Sun C-M, Belkaid Y, Powrie F. 2007. A functionally specialized population of mucosal CD103+ DC induces Foxp3+ regulatory T-cells via a TGFb and retinoic acid-dependent mechanism. J Exp Med. 204(8):1757–1764. doi: 10.1084/jem.20070590.
   PubMed Web of Science ®Google Scholar
• Ellebaek E, Engell-Noerregaard L, Iversen TZ, Froesig TM, Munir S, Hadrup SR, Andersen MH, Svane IM. 2012. Metastatic melanoma patients treated with dendritic cell vaccination, IL-2, and metronomic cyclophosphamide: Results from a Phase II trial. Cancer Immunol Immunother. 61(10):1791–1804. doi: 10.1007/s00262-012-1242-4.
   PubMed Web of Science ®Google Scholar
• Feau S, Facchinetti V, Granucci F, Citterio S, Jarrossay D, Seresini S, Protti MP, Lanzavecchia A, Ricciardi-Castagnoli P. 2005. Dendritic cell-derived IL-2 production is regulated by IL-15 in humans and in mice. Blood. 105(2):697–702. doi: 10.1182/blood-2004-03-1059.
   PubMed Web of Science ®Google Scholar
• Flanagan WM, Corthésy B, Bram RJ, Crabtree GR. 1991. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature. 352(6338):803–807. doi: 10.1038/352803a0.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. 2005. A function for IL-2 in Foxp3-expressing regulatory T-cells. Nat Immunol. 6(11):1142–1151. doi: 10.1038/ni1263.
   PubMed Web of Science ®Google Scholar
• Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. 2002. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 195(3):327–333. doi: 10.1084/jem.20010938.
   PubMed Web of Science ®Google Scholar
• Goodridge HS, Simmons RM, Underhill DM. 2007. Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J Immunol. 178(5):3107–3115. doi: 10.4049/jimmunol.178.5.3107.
   PubMed Web of Science ®Google Scholar
• Granucci F, Feau S, Angeli V, Trottein F, Ricciardi-Castagnoli P. 2003. Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming. J Immunol. 170(10):5075–5081. doi: 10.4049/jimmunol.170.10.5075.
   PubMed Web of Science ®Google Scholar
• Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, Virzi E, Rescigno M, Moro G, Ricciardi-Castagnoli P. 2001. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol. 2(9):882–888. doi: 10.1038/ni0901-882.
   PubMed Web of Science ®Google Scholar
• Granucci F, Zanoni I, Pavelka N, Van Dommelen SLH, Andoniou CE, Belardelli F, Degli Esposti MA, Ricciardi-Castagnoli P. 2004. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med. 200(3):287–295. doi: 10.1084/jem.20040370.
   PubMed Web of Science ®Google Scholar
• Han D, Walsh MC, Cejas PJ, Dang NN, Kim YF, Kim J, Charrier-Hisamuddin L, Chau L, Zhang Q, Bittinger K, et al. 2013. Dendritic cell expression of the signaling molecule TRAF6 is critical for gut microbiota-dependent immune tolerance. Immunity. 38(6):1211–1222. doi: 10.1016/j.immuni.2013.05.012.
   PubMed Web of Science ®Google Scholar
• Hsu PS, Lai CL, Hu M, Santner-Nanan B, Dahlstrom JE, Lee CH, Ajmal A, Bullman A, Arbuckle S, Al Saedi A, et al. 2018. IL-2 enhances gut homing potential of human naive regulatory T-cells early in life. J Immunol. 200(12):3970–3980. doi: 10.4049/jimmunol.1701533.
   PubMed Web of Science ®Google Scholar
• Inaba K, Granelli-Piperno A, Steinman RM. 1983. Dendritic cells induce T-lymphocytes to release B-cell-stimulating factors by an IL-2-dependent mechanism. J Exp Med. 158(6):2040–2057. doi: 10.1084/jem.158.6.2040.
   PubMed Web of Science ®Google Scholar
• Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, Umansky V. 2015. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer. 136(10):2352–2360. doi: 10.1002/ijc.29297.
   PubMed Web of Science ®Google Scholar
• Kalia V, Sarkar S. 2018. Regulation of effector and memory CD8 T-cell differentiation by IL-2-A balancing act. Front Immunol. 9:2987. doi: 10.3389/fimmu.2018.02987.
   PubMed Web of Science ®Google Scholar
• Kehrl JH, Dukovich M, Whalen G, Katz P, Fauci AS, Greene WC. 1988. Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells. J Clin Invest. 81(1):200–205.
   PubMed Web of Science ®Google Scholar
• Kumar V, Patel S, Tcyganov E, Gabrilovich DI. 2016. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37(3):208–220. doi: 10.1016/j.it.2016.01.004.
   PubMed Web of Science ®Google Scholar
• Mencarelli A, Khameneh HJ, Fric J, Vacca M, El Daker S, Janela B, Tang JP, Nabti S, Balachander A, Lim TS, et al. 2018. Calcineurin-mediated IL-2 production by CD11cMHCII myeloid cells is crucial for intestinal immune homeostasis. Nat Commun. 9(1):1102. doi: 10.1038/s41467-018-03495-3.
   PubMedGoogle Scholar
• Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI. 2006. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66(18):9299–9307. doi: 10.1158/0008-5472.CAN-06-1690.
   PubMed Web of Science ®Google Scholar
• Morel PA, Butterfield LH. 2015. Dendritic cell control of immune responses. Front Immunol. 6:42. doi: 10.3389/fimmu.2015.00042.
   PubMed Web of Science ®Google Scholar
• Nelson BH. 2004. IL-2, regulatory T-cells, and tolerance. J Immunol. 172(7):3983–3988. doi: 10.4049/jimmunol.172.7.3983.
   PubMed Web of Science ®Google Scholar
• Noubade R, Majri-Morrison S, Tarbell KV. 2019. Beyond cDC1: Emerging roles of DC crosstalk in cancer immunity. Front Immunol. 10:1014. doi: 10.3389/fimmu.2019.01014.
   PubMed Web of Science ®Google Scholar
• Owen DL, Mahmud SA, Vang KB, Kelly RM, Blazar BR, Smith KA, Farrar MA. 2018. Identification of cellular sources of IL-2 needed for regulatory T-cell development and homeostasis. J Immunol. 200(12):3926–3933. doi: 10.4049/jimmunol.1800097.
   PubMed Web of Science ®Google Scholar
• Raeber ME, Rosalia RA, Schmid D, Karakus U, Boyman O. 2020. Interleukin-2 signals converge in a lymphoid-dendritic cell pathway that promotes anticancer immunity. Sci Transl Med. 12:561. doi: 10.1126/scitranslmed.aba5464.
   Web of Science ®Google Scholar
• Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA, Pancisi E, Ancarani V, Fiammenghi L, Guidoboni M, et al. 2013. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25FoxP3+ regulatory T-cells in advanced melanoma patients. J Transl Med. 11(1):135. doi: 10.1186/1479-5876-11-135.
   PubMed Web of Science ®Google Scholar
• Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E, Williams DL, Gordon S, Tybulewicz VL, Brown GD, et al. 2005. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity. 22(4):507–517. doi: 10.1016/j.immuni.2005.03.004.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 313(23):1485–1492. doi: 10.1056/NEJM198512053132327.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. 2021. Correction to: A Journey in Science: Immersion in the search for effective cancer immunotherapies. Mol Med. 27(1):140. doi: 10.1186/s10020-021-00405-0.
   PubMed Web of Science ®Google Scholar
• Ross SH, Cantrell DA. 2018. Signaling and function of IL-2 in T-lymphocytes. Annu Rev Immunol. 36(1):411–433. doi: 10.1146/annurev-immunol-042617-053352.
   PubMedGoogle Scholar
• Sadlack B, Löhler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, Horak I. 1995. Generalized autoimmune disease in IL-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T-cells. Eur J Immunol. 25(11):3053–3059. doi: 10.1002/eji.1830251111.
   PubMed Web of Science ®Google Scholar
• Sauma D, Fierro A, Mora JR, Lennon-Duménil AM, Bono MR, Rosemblatt M, Morales J. 2003. Cyclosporine preconditions dendritic cells during differentiation and reduces IL-2 and IL-12 production following activation: A potential tolerogenic effect. Transplant Proc. 35(7):2515–2517. doi: 10.1016/j.transproceed.2003.09.020.
   PubMed Web of Science ®Google Scholar
• Schorey JS, Lawrence C. 2008. The pattern recognition receptor Dectin-1: From fungi to mycobacteria. Curr Drug Targets. 9(2):123–129. doi: 10.2174/138945008783502430.
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Davis MJ. 2017. Defective calcineurin/NFAT signaling in myeloid cells and susceptibility to aspergillosis in post-transplant patients. Virulence. 8(8):1498–1501. doi: 10.1080/21505594.2017.1380143.
   PubMed Web of Science ®Google Scholar
• Siegel JP, Puri RK. 1991. Interleukin-2 toxicity. J Clin Oncol. 9(4):694–704. doi: 10.1200/JCO.1991.9.4.694.
   PubMed Web of Science ®Google Scholar
• Slack EC, Robinson MJ, Hernanz-Falcón P, Brown GD, Williams DL, Schweighoffer E, Tybulewicz VL, Reis e Sousa C. 2007. Syk-dependent ERK activation regulates IL-2 and IL-10 production by DC stimulated with zymosan. Eur J Immunol. 37(6):1600–1612. doi: 10.1002/eji.200636830.
   PubMed Web of Science ®Google Scholar
• Smith KA. 1988. Interleukin-2: Inception, impact, and implications. Science. 240(4856):1169–1176. doi: 10.1126/science.3131876.
   PubMed Web of Science ®Google Scholar
• Spranger S, Dai D, Horton B, Gajewski TF. 2017. Tumor-residing Batf3 dendritic cells are required for effector T-cell trafficking and adoptive T-cell therapy. Cancer Cell. 31(5):711–723 e4. doi: 10.1016/j.ccell.2017.04.003.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Cohn ZA. 1973. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 137(5):1142–1162. doi: 10.1084/jem.137.5.1142.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kündig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, Schmits R, Simard JJ, Ohashi PS, Griesser H, et al. 1995. De-regulated T-cell activation and autoimmunity in mice lacking IL-2 receptor beta. Science. 268(5216):1472–1476. doi: 10.1126/science.7770771.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. 2017. Regulatory T-cells in cancer immunotherapy. Cell Res. 27(1):109–118. doi: 10.1038/cr.2016.151.
   PubMed Web of Science ®Google Scholar
• Umansky V, Blattner C, Gebhardt C, Utikal J. 2016. The role of Myeloid-Derived Suppressor Cells (MDSC) in cancer progression. Vaccines. 4(4):36. doi: 10.3390/vaccines4040036.
   PubMed Web of Science ®Google Scholar
• Wang L, Chang EWY, Wong SC, Ong S-M, Chong DQY, Ling KL. 2013. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol. 190(2):794–804. doi: 10.4049/jimmunol.1202088.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xiang Y, Xin VW, Wang X-W, Peng X-C, Liu X-Q, Wang D, Li N, Cheng J-T, Lyv Y-N, et al. 2020. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 13(1):107. doi: 10.1186/s13045-020-00939-6.
   PubMed Web of Science ®Google Scholar
• Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, et al. 2009. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci USA. 106(46):19455–19460. doi: 10.1073/pnas.0909474106.
   PubMed Web of Science ®Google Scholar
• Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, Sayers TJ, Murphy WJ, Wiltrout RH. 2014. Regulatory T-cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/alphaCD40 therapy. J Immunol. 192(12):5821–5829. doi: 10.4049/jimmunol.1400404.
   PubMed Web of Science ®Google Scholar
• Weist BM, Kurd N, Boussier J, Chan SW, Robey EA. 2015. Thymic regulatory T-cell niche size is dictated by limiting IL-2 from antigen-bearing dendritic cells and feedback competition. Nat Immunol. 16(6):635–641. doi: 10.1038/ni.3171.
   PubMed Web of Science ®Google Scholar
• Wuest SC, Edwan JH, Martin JF, Han S, Perry JSA, Cartagena CM, Matsuura E, Maric D, Waldmann TA, Bielekova B, et al. 2011. A role for IL-2 trans-presentation in dendritic cell-mediated T-cell activation in humans, as revealed by daclizumab therapy. Nat Med. 17(5):604–609. doi: 10.1038/nm.2365.
   PubMed Web of Science ®Google Scholar
• Zanoni I, Ostuni R, Capuano G, Collini M, Caccia M, Ronchi AE, Rocchetti M, Mingozzi F, Foti M, Chirico G, et al. 2009. CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature. 460(7252):264–268. doi: 10.1038/nature08118.
   PubMed Web of Science ®Google Scholar
• Zaslavsky A, Chou ST, Schadler K, Lieberman A, Pimkin M, Kim YJ, Baek K-H, Aird WC, Weiss MJ, Ryeom S, et al. 2013. The calcineurin-NFAT pathway negatively regulates megakaryopoiesis. Blood. 121(16):3205–3215. doi: 10.1182/blood-2012-04-421172.
   PubMed Web of Science ®Google Scholar
• Zelante T, Fric J, Wong AYW, Ricciardi-Castagnoli P. 2012. Interleukin-2 production by dendritic cells and its immuno-regulatory functions. Front Immunol. 3:161. doi: 10.3389/fimmu.2012.00161.
   PubMed Web of Science ®Google Scholar
• Zelante T, Wong AYW, Ping TJ, Chen J, Sumatoh HR, Viganò E, Hong Bing Y, Lee B, Zolezzi F, Fric J, et al. 2015. CD103 dendritic cells control TH17 cell function in the lung. Cell Rep. 12(11):1789–1801. doi: 10.1016/j.celrep.2015.08.030.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, Zhu J, Wei H, Zhao K. 2013. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One. 8(2):e57114. doi: 10.1371/journal.pone.0057114.
   PubMed Web of Science ®Google Scholar
• Zhou L, Chu C, Teng F, Bessman NJ, Goc J, Santosa EK, Putzel GG, Kabata H, Kelsen JR, Baldassano RN, et al. 2019. Innate lymphoid cells support regulatory T-cells in the intestine through interleukin-2. Nature. 568(7752):405–409. doi: 10.1038/s41586-019-1082-x.
   PubMed Web of Science ®Google Scholar